Metabolic Syndrome: Do Clinical Criteria Identify Similar Individuals Among Overweight Premenopausal Women?

Overview

Journal Metabolism

Specialty Endocrinology

Date 2007 Dec 15

PMID 18078858

Citations 5

Authors

Sofiya Alhassan

Alexandre Kiazand

Raymond R Balise

Abby C King

Gerald M Reaven

Christopher D Gardner

Affiliations

Soon will be listed here.

Abstract

The purpose of this analysis was to determine to what extent the clinical criteria for metabolic syndrome (MetSyn) proposed by the World Health Organization (WHO), the European Group for Study of Insulin Resistance (EGIR), the National Cholesterol Education Program Adult Treatment Panel III (ATP III), and the International Diabetes Foundation (IDF); triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio >/=3.0; and enlarged waist circumference (>/=88 cm) and elevated TG (>/=129 mg/dL) (EWET) identified similar or different overweight women and, secondarily, to examine the effect of 7% weight reduction on MetSyn status. Metabolic syndrome was determined among 256 premenopausal women (age = 41 +/- 6 years, body mass index [BMI] = 32 +/- 4 kg/m(2)) participating in a dietary weight loss clinical trial based on the clinical criteria proposed by WHO, EGIR, ATP III, and IDF. The prevalence of TG/HDL-C ratio >/=3.0 and EWET was determined and compared with MetSyn status. Based on the clinical criteria, 16.1% (EGIR), 20.7% (WHO), 31.0% (ATP III), and 31.8% (IDF) of participants met the criteria for MetSyn; 30.3% and 31.8% had TG/HDL-C >/=3.0 and EWET, respectively. Between 77% and 99% of participants were similarly classified across the clinical criteria. The highest and lowest agreements were between ATP III and IDF (kappa = 0.98; 95% confidence interval, 0.96-1.0) and WHO and IDF (kappa = 0.39; 95% confidence interval, 0.26-0.51), respectively. The TG/HDL-C ratio >/=3.0 and EWET moderately agreed with all 4 clinical criteria for MetSyn (kappa range, 0.36-0.59). Among those diagnosed with MetSyn at baseline, 64.0% to 75.0% of the participants who lost >/=7% and 25.8% to 55.6% of participants who lost <7% of their baseline body weight in 6 months no longer met the various clinical criteria for MetSyn, TG/HDL-C >/=3.0, or EWET. Our findings indicate that MetSyn varies substantially between clinical criteria, which raise questions about the clinical utility of these criteria. Regardless of MetSyn clinical criteria, >/=7% reduction in body weight has a beneficial impact on variables used to define MetSyn.

Citing Articles

Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome.

Yamagata K, Yamori Y Molecules. 2021; 26(19).

PMID: 34641407 PMC: 8512040. DOI: 10.3390/molecules26195863.

Lentil Sprouts Effect On Serum Lipids of Overweight and Obese Patients with Type 2 Diabetes.

Aslani Z, Mirmiran P, Alipur B, Bahadoran Z, Abbassalizade Farhangi M Health Promot Perspect. 2015; 5(3):215-24.

PMID: 26634200 PMC: 4667261. DOI: 10.15171/hpp.2015.026.

Lipid Variables Related to the Extent and Severity of Coronary Artery Disease in Non-Diabetic Turkish Cypriots.

Conkbayir C, Ayca B, Okcun E Iran J Public Health. 2015; 44(9):1196-203.

PMID: 26587493 PMC: 4645776.

Cardiovascular Risk in Women With PCOS.

Scicchitano P, Dentamaro I, Carbonara R, Bulzis G, Dachille A, Caputo P Int J Endocrinol Metab. 2013; 10(4):611-8.

PMID: 23843832 PMC: 3693634. DOI: 10.5812/ijem.4020.

Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study.

Zabetian A, Hadaegh F, Sarbakhsh P, Azizi F BMC Public Health. 2009; 9:138.

PMID: 19435528 PMC: 2696430. DOI: 10.1186/1471-2458-9-138.

References

Lorenzo C, Williams K, Hunt K, Haffner S . The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2006; 30(1):8-13. DOI: 10.2337/dc06-1414. View

Balkau B, Charles M . Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16(5):442-3. DOI: 10.1046/j.1464-5491.1999.00059.x. View

Schnell O, Standl E . Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract. 2006; 12 Suppl 1:16-9. DOI: 10.4158/EP.12.S1.16. View

Ford E . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005; 28(11):2745-9. DOI: 10.2337/diacare.28.11.2745. View

Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4):683-9. DOI: 10.2337/diacare.24.4.683. View

Dekker J, Girman C, Rhodes T, Nijpels G, Stehouwer C, Bouter L . Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112(5):666-73. DOI: 10.1161/CIRCULATIONAHA.104.516948. View

Ford E, Giles W . A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003; 26(3):575-81. DOI: 10.2337/diacare.26.3.575. View

Gardner C, Kiazand A, Alhassan S, Kim S, Stafford R, Balise R . Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA. 2007; 297(9):969-77. DOI: 10.1001/jama.297.9.969. View

Thom T, Haase N, Rosamond W, Howard V, Rumsfeld J, Manolio T . Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113(6):e85-151. DOI: 10.1161/CIRCULATIONAHA.105.171600. View

10.

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-52. DOI: 10.1161/CIRCULATIONAHA.105.169404. View

11.

Klein S, Burke L, Bray G, Blair S, Allison D, Pi-Sunyer X . Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology.... Circulation. 2004; 110(18):2952-67. DOI: 10.1161/01.CIR.0000145546.97738.1E. View

12.

Kahn H, Valdez R . Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr. 2003; 78(5):928-34. DOI: 10.1093/ajcn/78.5.928. View

13.

Diercks G, van Boven A, Hillege J, de Jong P, Rouleau J, van Gilst W . The importance of microalbuminuria as a cardiovascular risk indicator: A review. Can J Cardiol. 2002; 18(5):525-35. View

14.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

15.

CASTELLI W, DOYLE J, Gordon T, HAMES C, Hjortland M, Hulley S . HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977; 55(5):767-72. DOI: 10.1161/01.cir.55.5.767. View

16.

Meigs J, Wilson P, Nathan D, DAgostino Sr R, Williams K, Haffner S . Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003; 52(8):2160-7. DOI: 10.2337/diabetes.52.8.2160. View

17.

Wilson P, DAgostino R, Parise H, Sullivan L, Meigs J . Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112(20):3066-72. DOI: 10.1161/CIRCULATIONAHA.105.539528. View

18.

Carantoni M, Abbasi F, Reaven G . Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000; 23(2):171-5. DOI: 10.2337/diacare.23.2.171. View

19.

Ford E . Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005; 28(7):1769-78. DOI: 10.2337/diacare.28.7.1769. View

20.

McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G . Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism. 2004; 53(4):495-9. DOI: 10.1016/j.metabol.2003.10.032. View